Brief: Fortress Biotech, Cyprium Get FDA Acceptance for CUTX-101 NDA Resubmission
15/12/2025 14:24
Dec 15 (Reuters) - Fortress Biotech Inc FBIO.O: FORTRESS BIOTECH AND CYPRIUM THERAPEUTICS ANNOUNCE FDA ACCEPTANCE OF CUTX-101 NDA RESUBMISSION FORTRESS BIOTECH INC - PDUFA TARGET DATE FOR CUTX-101 SET FOR JANUARY 14, 2026 Source text: ID:nGNX3Nn1yb Further company coverage: FBIO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fortress Biotech
See all newsFortress Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Fortress Biotech Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Fortress Biotech And Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
Fortress Biotech Q1 net income jumps on PRV sale
Brief: Journey Medical Corporation Secures Contract With Third Major Gpo For Emrosi